arXivDaily arXiv每日学术速递 周一至周五更新
arXiv周末暂无论文更新,休息一下吧,周末愉快~~
arXiv 2005.01887q-bio.BMq-bio.QM
收藏

甲硅烷基化神经降压素类似物的中枢作用后无阿片类副作用的疼痛缓解

Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog

Pascal Tétreault, Élie Besserer-Offroy, Rebecca L. Brouillette, Adeline René, Alexandre Murza, Roberto Fanelli, Karyn Kirby, Alexandre J. Parent, Isabelle Dubuc… 展开作者

Pascal Tétreault, Élie Besserer-Offroy, Rebecca L. Brouillette, Adeline René, Alexandre Murza, Roberto Fanelli, Karyn Kirby, Alexandre J. Parent, Isabelle Dubuc, Nicolas Beaudet, Jérôme Côté, Jean-Michel Longpré, Jean Martinez, Florine Cavelier, Philippe Sarret

摘要:

神经降压素(NT)通过与NTS 1和NTS 2受体结合发挥纳洛酮不敏感的抗伤害作用,NT类似物在分子基础上提供比吗啡更强的疼痛缓解。在这里,我们研究了一种新的NT(8-13)衍生物JMV 2009的镇痛/不良反应,其中Pro 10残基被含硅的非天然氨基酸硅脯氨酸取代。我们首先报道了JMV 2009的合成和体外表征(受体-结合亲和力、功能活性和稳定性)。接下来,我们在一系列急性、强直性和慢性疼痛模型中检查了其镇痛活性。我们最终评估了其诱导与慢性阿片类药物使用相关的不良反应的能力,如便秘和镇痛耐受或与NTS 1激活相关的不良反应,如体温过低。在体外试验中,JMV 2009表现出对NTS 1和NTS 2的高结合亲和力,改善的蛋白水解抗性以及类似于NT的激动活性,诱导p42/p44 MAPK和受体内化的持续激活。鞘内注射JMV 2009在甩尾试验中产生剂量依赖性抗伤害性反应,并且几乎完全消除化学躯体和内脏伤害性刺激诱导的伤害性相关行为。同样,增加剂量的JMV 2009显著降低了神经损伤大鼠的触觉异常性疼痛和负重缺陷。重要的是,长期激动剂治疗不会导致镇痛耐受性的发展。此外,JMV 2009不会引起便秘,并且在诱导体温过低方面无效。这些发现表明,NT药物可以作为一种有效的无阿片类药物用于疼痛管理或可以作为辅助镇痛剂,以减少阿片类药物的不良反应。

英文摘要:

Neurotensin (NT) exerts naloxone-insensitive antinociceptive action through its binding to both NTS1 and NTS2 receptors and NT analogs provide stronger pain relief than morphine on a molecular basis. Here, we examined the analgesic/adverse effect profile of a new NT(8-13) derivative denoted JMV2009, in which the Pro10 residue was substituted by a silicon-containing unnatural amino acid silaproline. We first report the synthesis and in vitro characterization (receptor-binding affinity, functional activity and stability) of JMV2009. We next examined its analgesic activity in a battery of acute, tonic and chronic pain models. We finally evaluated its ability to induce adverse effects associated with chronic opioid use, such as constipation and analgesic tolerance or related to NTS1 activation, like hypothermia. In in vitro assays, JMV2009 exhibited high binding affinity for both NTS1 and NTS2, improved proteolytic resistance as well as agonistic activities similar to NT, inducing sustained activation of p42/p44 MAPK and receptor internalization. Intrathecal injection of JMV2009 produced dose-dependent antinociceptive responses in the tail-flick test and almost completely abolished the nociceptive-related behaviors induced by chemical somatic and visceral noxious stimuli. Likewise, increasing doses of JMV2009 significantly reduced tactile allodynia and weight bearing deficits in nerve-injured rats. Importantly, chronic agonist treatment did not result in the development of analgesic tolerance. Furthermore, JMV2009 did not cause constipation and was ineffective in inducing hypothermia. These findings suggest that NT drugs can act as an effective opioid-free medication for the management of pain or can serve as adjuvant analgesics to reduce the opioid adverse effects.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑